Used primarily in pharmaceutical research, this compound serves as a key intermediate in the synthesis of immunomodulatory drugs. It is notably involved in the development of agents that target protein degradation pathways, especially cereblon E3 ubiquitin ligase modulators. These agents are investigated for their potential in treating various cancers, including multiple myeloma and other hematological malignancies. The compound's structure enables selective binding to biological targets, enhancing the degradation of disease-causing proteins. It also supports the design of novel therapeutics with improved potency and reduced side effects. Research applications include structure-activity relationship studies and the optimization of drug candidates for clinical use.